The ghrelin axis — real biology, modest expectations

What the GH-axis peptides reliably do

The class — GHRH analogs (sermorelin, CJC-1295, tesamorelin), ghrelin/GHS-R agonists (ipamorelin, hexarelin, MK-677, anamorelin), and combinations — produces a biochemical effect that is genuinely well-established: dose-dependent elevation of endogenous growth hormone and downstream IGF-1.

The Teichman 2006, Ionescu 2006, Raun 1998, and other foundational papers each showed that the relevant hormone elevations occur reliably in human pharmacology studies. The biology of GH-axis stimulation is one of the better-characterized areas in peptide pharmacology.

Where the translation gets harder

The question that matters for users is not whether GH and IGF-1 rise — they do — but what those biochemical changes translate to in terms of clinical outcomes. The translational record is more nuanced:

• Anamorelin Phase 3 — In cancer cachexia, anamorelin reliably increased lean body mass and weight. It failed to improve handgrip strength (a co-primary endpoint) and was therefore not approved by the FDA or EMA, despite Japanese approval.
• MK-677 in elderly populations — Multiple Phase 3 studies in elderly and hip-fracture patients showed reliable GH/IGF-1 elevation but inconsistent effects on functional outcomes, with significant fluid retention and insulin sensitivity concerns.
• Tesamorelin in HIV lipodystrophy — Among the cleanest GH-axis success stories, with FDA approval for visceral-fat reduction in HIV-related lipodystrophy. The success is in a narrow population with a specific physiological abnormality, not a general body-composition tool.
• CJC-1295 + ipamorelin in healthy adults — No published RCT evidence for body-composition or functional outcomes despite extensive pharmacology characterization. Most clinical evidence remains at the biomarker level.

The long-term IGF-1 question

Sustained IGF-1 elevation is associated in epidemiologic literature with several long-term concerns: increased cancer risk in some populations, reduced insulin sensitivity, and in extremes (acromegaly), specific cardiovascular and tissue-overgrowth effects. The biochemical signal that GH-axis peptides produce at typical research-protocol doses is well below acromegaly territory but well above natural baseline. What that means over years of chronic use in healthy adults is not well-characterized in the peer-reviewed literature.

Where the class is actually useful

• Specific medical indications. Tesamorelin in HIV lipodystrophy is the clearest example. Adult GH deficiency is another. These are genuine clinical use cases with strong evidence.
• Sleep-architecture support. Some users report meaningful improvements in slow-wave sleep with evening GHRH-analog dosing, consistent with GH's natural pulsatile pattern. The signal is real if modest.
• Mild body-composition effects over months. In disciplined users with foundational nutrition and training in place, GH-axis peptides may produce small additional improvements in body composition. The effect is small relative to the foundations.

How to read the marketing claims

The honest framing distinguishes well-evidenced claims from speculative ones:

• Well-evidenced: GH-axis peptides raise GH and IGF-1; tesamorelin reduces visceral fat in HIV lipodystrophy; some users experience meaningful sleep improvements.
• Plausible but limited: Modest body-composition effects over months in disciplined users.
• Outpaces evidence: "Anti-aging," dramatic body-recomposition claims, broad recovery effects in healthy adults without controlled-trial support.